Uterine Rejuvenation with PRP: Endometrial Regeneration & IVF

Uterine rejuvenation with PRP is an increasingly important area of regenerative reproductive medicine, particularly for women experiencing persistent thin endometrium, difficult endometrial development or repeated implantation failure.

Successful IVF depends on more than producing a good embryo.

For pregnancy to begin, the embryo must interact successfully with a receptive and biologically active endometrium—the specialized tissue lining the inside of the uterus.

In some women, this endometrial environment does not develop optimally despite conventional preparation.

The lining may remain persistently thin. Previous uterine procedures may have damaged the tissue. Repeated transfers of apparently good-quality embryos may have failed. In other cases, the endometrium may reach an acceptable thickness but still raise concerns regarding vascularity, tissue quality or receptivity.

These clinical challenges have stimulated interest in regenerative approaches designed to support the endometrium at a biological level.

One of the most extensively studied of these approaches is Platelet-Rich Plasma, or PRP.

Rather than focusing exclusively on increasing endometrial thickness, uterine PRP aims to use the patient’s own platelet-derived growth factors and signaling molecules to support processes involved in tissue repair, angiogenesis, cellular proliferation and endometrial regeneration.

What Is Uterine Rejuvenation?

The endometrium is one of the most regenerative tissues in the human body.

Throughout reproductive life, it repeatedly grows, differentiates, sheds and regenerates under hormonal control.

This remarkable ability depends on several coordinated biological processes, including:

• Endometrial cell proliferation
• Formation and remodeling of blood vessels
• Stromal-cell activity
• Growth-factor signaling
• Extracellular matrix remodeling
• Immune regulation
• Hormonal responsiveness
• Cellular repair

When these mechanisms function normally, the endometrium can prepare itself for embryo implantation during each cycle.

However, previous injury, intrauterine adhesions, chronic inflammation, impaired vascular development or individual biological factors may interfere with this regenerative capacity.

Uterine rejuvenation refers to approaches designed to support these regenerative processes and improve the biological environment in which embryo implantation occurs.

PRP has become particularly relevant because platelets naturally contain a wide range of molecules involved in tissue healing and regeneration.

What Is Platelet-Rich Plasma?

Platelet-Rich Plasma (PRP) is prepared from a patient’s own blood.

A blood sample is processed—usually through controlled centrifugation—to separate and concentrate the platelet-containing plasma fraction.

Platelets are best known for their role in blood clotting, but they also contain biologically active molecules stored within intracellular granules.

When activated, platelets can release growth factors and signaling proteins involved in repair and regeneration.

These include molecules associated with:

• Cell proliferation
• Angiogenesis
• Tissue remodeling
• Cell migration
• Extracellular matrix production
• Inflammatory regulation
• Wound healing

Because PRP is autologous, the biological material originates from the patient’s own blood.

Its regenerative properties have led to applications across several medical fields and, increasingly, reproductive medicine.

How Does Uterine Rejuvenation with PRP Work?

In uterine rejuvenation with PRP, a carefully prepared platelet-rich fraction is introduced into the uterine cavity using a thin catheter.

The aim is to expose the endometrial surface to a concentrated environment of platelet-derived signaling molecules.

Once activated, platelets release numerous biological mediators capable of interacting with endometrial cells.

Several mechanisms are particularly relevant to fertility.

Angiogenesis

Angiogenesis is the formation of new blood vessels.

The developing endometrium requires an adequate vascular network to provide oxygen, nutrients and molecular signals.

Platelet-associated growth factors may support endothelial-cell activity and vascular development, making angiogenesis one of the most important proposed mechanisms of uterine PRP.

Cellular proliferation

The endometrium must proliferate rapidly during the first part of the menstrual cycle.

Growth factors released from platelets may influence stromal and epithelial cells involved in rebuilding the endometrial tissue.

Tissue repair

PRP has long been studied in regenerative medicine because platelet-derived factors participate naturally in wound healing.

This makes PRP particularly interesting for women whose poor endometrial development may be related to previous uterine injury.

Extracellular matrix remodeling

Cells within the endometrium exist within a complex extracellular structure.

Regeneration requires controlled remodeling of this environment, another process influenced by growth-factor signaling.

Modulation of inflammation

Implantation requires carefully regulated inflammatory and immune signaling.

Platelet-derived mediators may influence local inflammatory pathways and contribute to tissue recovery and regeneration.

Together, these mechanisms provide the biological basis for using PRP to support endometrial development.

Who May Benefit from Uterine Rejuvenation with PRP?

Uterine PRP is particularly relevant when there is evidence that the endometrial environment may be limiting embryo transfer or implantation.

Potential candidates may include women with:

• Persistently thin endometrium
• Repeated difficulty reaching an appropriate lining before transfer
• Recurrent implantation failure
• Previous unsuccessful embryo transfers
• Endometrial injury after uterine procedures
• Previous intrauterine adhesions after appropriate treatment
• A history of difficult endometrial preparation
• Selected cases where endometrial regeneration appears suboptimal

Patient selection is important.

A woman whose main limitation is embryo aneuploidy presents a different clinical situation from a woman repeatedly producing an endometrium of 5–6 mm despite adequate hormonal preparation.

Likewise, a patient with untreated intrauterine adhesions requires different management from a woman whose uterine cavity is anatomically normal but whose endometrial development remains persistently poor.

The role of PRP is therefore best determined within the context of the patient’s complete reproductive history.

Uterine Rejuvenation with PRP for Thin Endometrium

One of the most studied applications of uterine PRP is thin endometrium.

Endometrial thickness is usually assessed by transvaginal ultrasound during preparation for embryo transfer.

Although approximately 7 mm is frequently used in research as a threshold for thin endometrium, implantation does not suddenly become impossible below a single numerical value.

Instead, endometrial thickness appears to behave as a continuum: reproductive outcomes tend to improve across increasing thickness ranges, while pregnancies can still occur with thinner linings.

The difficulty arises when a patient’s lining remains persistently thin despite appropriate hormonal preparation.

In these situations, simply increasing the estrogen dose may not always solve the underlying problem.

PRP introduces a different biological strategy.

Rather than relying exclusively on hormonal stimulation, it aims to support the regenerative capacity, cellular activity and vascular environment of the endometrium.

This is why PRP has become particularly relevant for women whose endometrium repeatedly fails to respond adequately to conventional preparation.

What Does Research Show for Thin Endometrium?

Clinical research on intrauterine PRP has expanded substantially.

Randomized trials and meta-analyses have reported increases in endometrial thickness after PRP treatment together with improvements in reproductive outcomes in selected women with difficult endometrial development.

Research has also moved beyond thickness alone.

A 2025 randomized controlled trial comparing single and double intrauterine PRP administration in women with thin endometrium examined not only endometrial thickness but also receptivity, pregnancy outcomes and endometrial hemodynamics. The study reported measurable improvements in endometrial and early pregnancy outcomes, demonstrating growing interest in optimizing not simply whether PRP is used, but also how and when it is administered.

This is an important evolution.

The question is increasingly shifting from:

“Does PRP make the endometrium thicker?”

to:

“How can PRP protocols be optimized for the right patient and the right clinical situation?”

Recurrent Implantation Failure and the Endometrial Environment

Recurrent implantation failure is another major area in which uterine PRP has been studied.

Successful embryo implantation depends on interaction between two biological systems:

the embryo and the endometrium.

Embryo competence remains critically important, but when good-quality or euploid embryos repeatedly fail to implant, assessment of the uterine and endometrial environment becomes increasingly relevant.

The endometrium contributes through processes involving:

• Adhesion molecules
• Cytokine signaling
• Growth factors
• Angiogenesis
• Immune regulation
• Stromal-cell differentiation
• Cellular communication with the embryo

PRP potentially influences several of these same biological pathways.

This overlap provides the rationale for investigating uterine rejuvenation with PRP in women with recurrent implantation failure.

What Does Recent Research Show for Recurrent Implantation Failure?

The evidence in recurrent implantation failure has become increasingly substantial.

A 2026 meta-analysis of 10 randomized controlled trials involving 1,188 women found that intrauterine autologous PRP was associated with significantly higher clinical-pregnancy and live-birth rates than control treatment. The clinical pregnancy relative risk was 2.23, while the live-birth relative risk was 3.74 in the pooled analysis.

A separate 2026 systematic review and meta-analysis likewise found higher biochemical pregnancy, clinical pregnancy, ongoing pregnancy and live-birth rates among women receiving intrauterine PRP. The analysis suggested particularly favorable results in some subgroups, including blastocyst transfer and women with a greater number of previous implantation failures.

An umbrella review published in 2026, examining 15 systematic reviews, also found an overall beneficial direction for implantation, clinical pregnancy and live birth. It highlighted, however, that evidence quality and methodological consistency vary considerably between reviews.

Taken together, the evolving literature presents PRP as a promising regenerative tool for appropriately selected patients, while also demonstrating why treatment protocol, patient selection and clinical experience are important.

PRP Is More Than an Endometrial “Thickness Treatment”

Reducing uterine PRP to a method for adding millimeters to the endometrium misses much of its biological rationale.

The endometrium is a living and highly active tissue.

Its ability to support implantation depends on far more than its ultrasound measurement.

Important characteristics include:

• Vascularization
• Cellular health
• Stromal function
• Hormonal responsiveness
• Growth-factor signaling
• Extracellular matrix organization
• Immune balance
• Embryo-endometrial communication

PRP influences pathways involved in several of these processes.

For this reason, the term uterine rejuvenation better describes the broader objective: supporting the biological environment and regenerative behavior of the endometrium.

Uterine PRP After Previous Endometrial Injury

Some of the most challenging cases of thin endometrium occur after damage to the uterine cavity.

Potential causes include:

• Dilation and curettage
• Surgery within the uterus
• Previous retained pregnancy tissue
• Intrauterine adhesions
• Infection
• Endometrial trauma

When the basal layer of the endometrium is damaged, normal regeneration may become impaired.

Intrauterine adhesions should first be appropriately evaluated and treated when present.

After correction of the structural problem, however, some women continue to have difficulty developing an adequate endometrium.

This is an area where regenerative support becomes especially relevant.

Platelet-derived growth factors involved in repair, angiogenesis and cellular proliferation provide a biological rationale for using PRP as part of the endometrial recovery strategy.

How Is Uterine PRP Performed?

Protocols can vary according to the patient’s condition and the fertility centre.

A typical procedure involves several steps.

1. Blood collection

A relatively small amount of the patient’s blood is collected.

2. PRP preparation

The sample is processed to separate and concentrate the platelet-containing plasma fraction.

The exact centrifugation method, platelet concentration and preparation protocol can influence the biological characteristics of the final product.

3. Intrauterine administration

The prepared PRP is introduced into the uterine cavity using a thin catheter, in a procedure similar in principle to an embryo-transfer catheterization.

4. Endometrial reassessment

Ultrasound may subsequently be used to evaluate endometrial development.

5. Embryo-transfer planning

According to the patient’s response and treatment protocol, embryo transfer can then be coordinated with endometrial preparation.

Some treatment protocols involve a single infusion, while others use repeated administrations.

Current research is increasingly examining the optimal timing, concentration and number of PRP applications.

Why PRP Preparation Matters

Not all preparations described as “PRP” are necessarily biologically identical.

Differences can occur in:

• Blood volume collected
• Centrifugation technique
• Number of centrifugation steps
• Final platelet concentration
• Presence or absence of leukocytes
• Activation method
• Volume administered
• Timing relative to embryo transfer
• Number of applications

These differences help explain why study results can vary.

They also highlight the importance of clinical experience and standardized preparation protocols.

Regenerative fertility treatment involves more than simply obtaining platelet-rich plasma.

The preparation needs to be integrated into a carefully planned reproductive treatment strategy.

When Is PRP Used During an IVF Cycle?

The timing depends on the reason for treatment.

In women with thin endometrium, PRP may be administered during the proliferative phase of endometrial preparation before progesterone begins.

The response can then be evaluated before embryo transfer.

Depending on endometrial development and the specific protocol, a second administration may sometimes be considered.

For women with recurrent implantation failure but acceptable endometrial thickness, the treatment objective may focus more broadly on the uterine microenvironment rather than simply increasing the ultrasound measurement.

The protocol should therefore reflect the patient’s biological problem.

Uterine Rejuvenation with PRP Before Frozen Embryo Transfer

PRP is particularly compatible with frozen embryo transfer (FET) because the embryo-transfer cycle provides time to focus specifically on preparing the endometrium.

Frozen embryo transfer may be performed during:

• A natural cycle
• A modified-natural cycle
• A programmed hormonal cycle

If PRP is included, it can be incorporated into the endometrial preparation phase and the response assessed before transfer.

This approach enables the fertility team to separate two important components of IVF:

embryo creation and uterine preparation.

For women with previously created embryos and persistent endometrial difficulty, this can allow treatment to focus specifically on improving the environment into which the embryo will be transferred.

Does PRP Improve Endometrial Blood Flow?

This is an increasingly interesting area of research.

Platelet-derived factors include molecules involved in angiogenesis and endothelial-cell activity.

Because healthy endometrial growth requires adequate vascular development, improved blood flow may be one mechanism through which PRP supports tissue function.

Recent clinical studies have therefore evaluated endometrial and uterine hemodynamic parameters, not simply lining thickness.

This broader assessment is valuable because regeneration involves both tissue quantity and tissue quality.

PRP and Endometrial Receptivity

Endometrial receptivity describes the temporary biological state during which the endometrium can interact successfully with an embryo.

It involves:

• Changes in gene expression
• Cellular differentiation
• Adhesion molecules
• Growth factors
• Cytokines
• Immune-cell activity
• Vascular adaptation

PRP contains biological mediators capable of interacting with several of these pathways.

The potential effect on receptivity may therefore be more complex than a simple increase in endometrial thickness.

Current studies examining molecular markers, blood flow and pregnancy outcomes are helping researchers understand these effects more precisely.

Uterine Rejuvenation with PRP and Repeated Failed Transfers

A patient who has experienced several unsuccessful embryo transfers requires a systematic assessment.

PRP should form part of that larger clinical picture rather than replacing investigation.

Important factors include:

• Female age
• Embryo morphology
• PGT-A status when relevant
• Number of previous embryo transfers
• Uterine anatomy
• Endometrial thickness
• History of intrauterine surgery
• Endometriosis or adenomyosis when relevant
• Male fertility factors
• Previous pregnancy history

Once these factors have been reviewed, uterine PRP can be integrated into a personalized strategy when the endometrial environment represents a reasonable therapeutic target.

This approach is particularly relevant when repeated implantation failure and difficult endometrial development overlap.

Regenerative Fertility Experience at Chania Fertility Unit

At Chania Fertility Unit, regenerative reproductive medicine forms an important part of the clinic’s fertility strategy under the scientific direction of Dr Matthaios Fraidakis.

Dr Fraidakis, who is also Scientific Director of Crete Fertility Centre in Heraklion, has extensive clinical experience with regenerative approaches to female fertility dating back to 2016.

This long-term experience is important because regenerative fertility treatment is not simply a single procedure applied identically to every woman.

Patient selection, preparation methods, treatment timing and integration with IVF all influence the clinical strategy.

For example:

• A patient with diminished ovarian reserve requires an ovarian-focused approach.
• A woman with persistent thin endometrium requires an endometrial strategy.
• A patient with recurrent implantation failure despite an apparently normal lining requires broader assessment of the embryo-endometrial interaction.
• Previous uterine injury introduces another biological context.

Clinical experience allows regenerative treatment to be matched more closely to the patient’s underlying fertility problem.

From Ovarian Rejuvenation to Uterine Rejuvenation

Regenerative reproductive medicine can target different parts of the reproductive system.

Ovarian rejuvenation focuses on ovarian tissue and its microenvironment.

Uterine rejuvenation focuses on the endometrium and uterine environment involved in implantation.

The biological mechanisms overlap in several areas:

• Growth-factor signaling
• Angiogenesis
• Cellular proliferation
• Tissue remodeling
• Inflammatory regulation
• Intercellular communication

However, the therapeutic target is different.

This is important when developing an individualized treatment program.

A woman with low AMH and a healthy endometrium should not automatically receive the same regenerative strategy as a woman with good embryos but a persistently thin uterine lining.

PRP, Exosomes and Stem Cells in Endometrial Regeneration

PRP is one component of a broader regenerative medicine field.

Other approaches being explored include exosomes and stem-cell-based therapies.

Although their regenerative objectives may overlap, their biological mechanisms differ.

PRP

PRP delivers concentrated platelets and their associated growth factors and signaling molecules.

It is autologous and can be prepared directly from the patient’s blood.

Exosomes

Exosomes are microscopic extracellular vesicles that transport proteins, lipids, RNA and other signaling molecules between cells.

They play an important role in cellular communication and are being studied for their potential effects on angiogenesis, inflammation and tissue regeneration.

Stem-cell-based approaches

Stem cells and mesenchymal stromal cells can release a broad range of regenerative signals.

Many of their effects appear to occur through paracrine mechanisms—signals released by the cells that influence surrounding tissue.

These areas are closely connected scientifically.

Understanding how platelets, extracellular vesicles and regenerative cells communicate with reproductive tissues is helping fertility medicine move toward increasingly targeted biological treatments.

Why Patient Selection Matters

Not every unsuccessful embryo transfer has an endometrial cause.

Likewise, not every thin endometrium has the same underlying mechanism.

Before considering uterine PRP, important questions include:

• Is the uterine cavity structurally normal?
• Are adhesions present?
• Is there a history of endometrial injury?
• How thin has the lining remained in previous cycles?
• Has changing hormonal preparation helped?
• Have good-quality or euploid embryos previously failed to implant?
• Is adenomyosis or another uterine condition relevant?
• Has pregnancy occurred before?
• What is the patient’s age and embryo prognosis?

The stronger the evidence that the uterine or endometrial environment represents a limiting factor, the clearer the rationale for targeting it.

How Many PRP Treatments Are Needed?

There is no single protocol that applies to every patient.

Research studies have used different regimens, including one or more intrauterine administrations.

A 2025 randomized controlled trial directly compared single and double PRP administration in women with thin endometrium, illustrating the increasing focus on optimizing dosage and scheduling.

In clinical practice, the number of administrations may depend on:

• Initial endometrial thickness
• Previous response
• Underlying uterine history
• Timing of embryo transfer
• Endometrial development after the first treatment
• The protocol used by the fertility centre

Treatment should therefore be individualized rather than defined by a universal number of infusions.

Is the PRP Taken from the Patient Herself?

Yes.

In conventional autologous PRP, the blood used to prepare the platelet-rich fraction comes from the patient.

This is one of the attractive characteristics of the technique.

The treatment uses biological material already present in the patient’s circulation but concentrates selected components associated with regeneration and tissue repair.

Does Uterine PRP Guarantee Implantation?

No fertility treatment can guarantee embryo implantation.

Even under excellent conditions, implantation still depends on the biological competence of the embryo as well as the uterine environment.

The clinical objective of uterine rejuvenation with PRP is therefore to improve or support factors within the endometrium that may be modifiable.

For the right patient, this can address an important component of the implantation pathway.

The realistic goal is not certainty.

It is to create a more favorable uterine environment before transfer.

Frequently Asked Questions About Uterine Rejuvenation with PRP

What is uterine rejuvenation with PRP?

Uterine rejuvenation with PRP involves introducing autologous Platelet-Rich Plasma into the uterine cavity to expose the endometrium to concentrated platelet-derived growth factors and signaling molecules associated with tissue repair, angiogenesis and regeneration.

Can PRP increase endometrial thickness?

Clinical trials and meta-analyses have reported increased endometrial thickness in women with persistent thin endometrium following intrauterine PRP. Individual responses vary, and treatment evaluation increasingly considers vascularity, receptivity and pregnancy outcomes in addition to thickness alone.

Can PRP help recurrent implantation failure?

Recent randomized-trial meta-analyses report higher clinical-pregnancy and live-birth rates among women with recurrent implantation failure treated with intrauterine PRP compared with controls. A 2026 meta-analysis involving 1,188 women reported significant improvements in both outcomes.

How does PRP regenerate the endometrium?

Platelets release growth factors and signaling proteins involved in angiogenesis, cellular proliferation, tissue remodeling, wound healing and inflammatory regulation. These mechanisms may support endometrial regeneration and improve the uterine environment.

Is PRP used only for thin endometrium?

No. Thin endometrium is one of its principal applications in reproductive medicine, but intrauterine PRP has also been studied in women with recurrent implantation failure and repeated unsuccessful embryo transfers.

Is uterine PRP the same as ovarian PRP?

No.

Both use PRP, but the biological target is different.

Ovarian PRP is directed toward ovarian tissue and ovarian function.

Uterine PRP is directed toward the endometrium and the environment required for embryo implantation.

When is PRP performed before embryo transfer?

Timing varies according to the treatment protocol. It is generally incorporated into the endometrial preparation period before embryo transfer, with subsequent evaluation of the lining and response.

Is one PRP treatment enough?

For some patients a single administration may be used, while other protocols use repeated treatment according to endometrial response. Research is continuing to refine the most effective scheduling strategies.

Can PRP help after uterine injury?

PRP’s regenerative mechanisms make it particularly interesting in women with impaired endometrial development following previous uterine injury. Structural problems such as adhesions need appropriate evaluation and treatment, after which regenerative support may be considered according to the individual case.

What is the difference between PRP and exosome therapy?

PRP provides concentrated platelets and platelet-derived biological factors from the patient’s own blood. Exosome therapy focuses on extracellular vesicles containing molecular signals involved in communication between cells. Both target regenerative pathways through different biological mechanisms.

Uterine Rejuvenation with PRP: Supporting the Environment for Implantation

Uterine rejuvenation with PRP represents an important shift in the way difficult endometrial problems can be approached.

Traditional endometrial preparation has focused primarily on hormones and ultrasound measurements.

These remain essential.

But modern regenerative reproductive medicine recognizes that the endometrium is far more than a measurement in millimeters.

It is a dynamic biological tissue dependent on cellular proliferation, vascular development, growth-factor signaling, tissue remodeling, immune balance and embryo-endometrial communication.

PRP targets several of these regenerative pathways simultaneously.

Growing clinical research has reported encouraging results for women with thin endometrium and recurrent implantation failure, including improvements in endometrial development, implantation, clinical pregnancy and live birth in selected study populations.

At Chania Fertility Unit, uterine rejuvenation can be considered within an individualized fertility strategy under the scientific direction of Dr Matthaios Fraidakis, whose experience with regenerative approaches to female fertility extends back to 2016.

The objective is not simply to make the endometrium thicker.

It is to evaluate the patient’s previous IVF and implantation history, identify whether the uterine environment represents an important limiting factor, and use regenerative medicine to support the biological conditions required for successful embryo implantation and pregnancy.